the data we've all been waiting for
is 501Y.V2 is less susceptible to neutralisation by convalescent sera than the original SARS-CoV-2 D614G lineage seen in South Africa?
short answer: yes 1/5
biorxiv.org/content/10.110…
is 501Y.V2 is less susceptible to neutralisation by convalescent sera than the original SARS-CoV-2 D614G lineage seen in South Africa?
short answer: yes 1/5
biorxiv.org/content/10.110…
panel a is 3 pie charts, sera from 44 patients
left pie chart shows neutralisation of original D614G variant by convalescent sera: dark blue= high neutralisation titres, and light blue = lower titres 2/5
left pie chart shows neutralisation of original D614G variant by convalescent sera: dark blue= high neutralisation titres, and light blue = lower titres 2/5
right pie chart shows neutralisation of 501Y.V2 variant by same convalescent sera samples: red means loss of neutralising activity (red/black in columns below)
this loss is seen in 21/44 (48%) of total patient samples; only 3 samples retain high neutralising activity 3/5
this loss is seen in 21/44 (48%) of total patient samples; only 3 samples retain high neutralising activity 3/5
the implication is that neutralising antibodies elicited by vaccine (based on original SARS-CoV-2 sequence) may be less effective
key caveats of poorly understood role of non-neutralizing antibodies (retained with 501Y.V2 variant) and the efficacy of T cell responses 4/5
key caveats of poorly understood role of non-neutralizing antibodies (retained with 501Y.V2 variant) and the efficacy of T cell responses 4/5
great study turned around incredibly quickly by Constantinos Kurt Wibmer and team @nicd_sa 5/5
• • •
Missing some Tweet in this thread? You can try to
force a refresh
